According to the company’s semi-annual financial report, Hengrui Pharmaceutical invested 2.581 billion yuan in R&D in the first half of the year, a year-on-year increase of 38.48%. The proportion of R&D investment in sales revenue reached 19.41%, a record high. Driven by huge investment in R&D, the company achieved fruitful R&D results in the first half of the year.
In the first half of the year, Hengrui Medicine obtained 5 production approvals for innovative pharmaceutical preparations, 9 production approvals for generic pharmaceutical preparations, obtained 41 drug clinical approvals and 10 product consistency evaluation approvals, and completed 2 It has carried out consistency evaluation application work for a variety of products, and has carried out more than 240 clinical projects at home and abroad, with considerable R&D stock. At the same time, 131 new domestic patent applications and 39 new international PCT applications were submitted, and 64 domestic and 59 foreign authorizations were obtained.